Login to Your Account

Quad Doesn't Disappoint: 4Q NDA Filing on Tap for Gilead

By Marie Powers

Wednesday, September 21, 2011
The second pivotal Phase III trial (Study 103) of the HIV Quad regimen (elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate) under development by Gilead Sciences Inc. met the expectations of the company and most analysts by demonstrating noninferiority – though not superiority – at week 48 compared to ritonavir-boosted atazanavir plus Truvada (emtricitabine/tenofovir disoproxil fumarate). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription